Evidence map›Paper›PMID 35626377›Full record

ReviewDiagnostics (Basel, Switzerland)2022

Utility of Bulk T-Cell Receptor Repertoire Sequencing Analysis in Understanding Immune Responses to COVID-19.

Hannah Kockelbergh, Shelley Evans, Tong Deng, Ella Clyne, Anna Kyriakidou, Andreas Economou, Kim Ngan Luu Hoang, Stephen Woodmansey, Andrew Foers, Anna Fowler and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Hannah KockelberghDepartment of Health Data Science, Institute of Population Health, University of Liverpool, Liverpool L69 3GF, UK.
Shelley EvansDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.ORCID 0000-0003-3242-6017
Tong DengDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Ella ClyneDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.ORCID 0000-0001-8945-4508
Anna KyriakidouSchool of Clinical Medicine, University of Cambridge, Cambridge CB2 1QP, UK.ORCID 0000-0001-8964-8345
Andreas EconomouSchool of Clinical Medicine, University of Cambridge, Cambridge CB2 1QP, UK.ORCID 0000-0002-3305-5804
Kim Ngan Luu HoangDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.ORCID 0000-0001-5670-1832
Stephen WoodmanseyDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Andrew FoersKennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7YF, UK.ORCID 0000-0002-5036-7906
Anna FowlerDepartment of Health Data Science, Institute of Population Health, University of Liverpool, Liverpool L69 3GF, UK.
Elizabeth J SoilleuxDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.ORCID 0000-0002-4032-7249
University of Cambridge · GBUniversity of Liverpool · GBUniversity Hospitals of Morecambe Bay NHS Foundation Trust · GBUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measuring immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19), can rely on antibodies, reactive T cells and other factors, with T-cell-mediated responses appearing to have greater sensitivity and longevity. Because each T cell carries an essentially unique nucleic acid sequence for its T-cell receptor (TCR), we can interrogate sequence data derived from DNA or RNA to assess aspects of the immune response. This review deals with the utility of bulk, rather than single-cell, sequencing of TCR repertoires, considering the importance of study design, in terms of cohort selection, laboratory methods and analysis. The advances in understanding SARS-CoV-2 immunity that have resulted from bulk TCR repertoire sequencing are also be discussed. The complexity of sequencing data obtained by bulk repertoire sequencing makes analysis challenging, but simple descriptive analyses, clonal analysis, searches for specific sequences associated with immune responses to SARS-CoV-2, motif-based analyses, and machine learning approaches have all been applied. TCR repertoire sequencing has demonstrated early expansion followed by contraction of SARS-CoV-2-specific clonotypes, during active infection. Maintenance of TCR repertoire diversity, including the maintenance of diversity of anti-SARS-CoV-2 response, predicts a favourable outcome. TCR repertoire narrowing in severe COVID-19 is most likely a consequence of COVID-19-associated lymphopenia. It has been possible to follow clonotypic sequences longitudinally, which has been particularly valuable for clonotypes known to be associated with SARS-CoV-2 peptide/MHC tetramer binding or with SARS-CoV-2 peptide-induced cytokine responses. Closely related clonotypes to these previously identified sequences have been shown to respond with similar kinetics during infection. A possible superantigen-like effect of the SARS-CoV-2 spike protein has been identified, by means of observing V-segment skewing in patients with severe COVID-19, together with structural modelling. Such a superantigen-like activity, which is apparently absent from other coronaviruses, may be the basis of multisystem inflammatory syndrome and cytokine storms in COVID-19. Bulk TCR repertoire sequencing has proven to be a useful and cost-effective approach to understanding interactions between SARS-CoV-2 and the human host, with the potential to inform the design of therapeutics and vaccines, as well as to provide invaluable pathogenetic and epidemiological insights.

Indexed as

antibodycoronavirusCOVID-19diversityimmune responseimmunological memoryimmunoreceptormachine learningSARS-CoV-2T-cell receptor repertoire

Identifiers

PMID35626377
PMCPMC9140453
OpenAlexW4280591297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.